-
Discovery that Neuropilin b1 domain acts as a binding site for SARS-CoV-2 Spike protein and aids viral entry. Lead therapeutic candidate, ATYR1923, modulates Neuropilin pathway to dampen inflammatory responses. SAN DIEGO , June 17, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc.
-
Trial opens for enrollment of hospitalized patients at multiple centers throughout the U.S. SAN DIEGO , June 15, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological
-
Poster details data from aTyr’s pre-clinical, domain specific Neuropilin-2 (NRP2) antibody program highlighting therapeutic potential in triple-negative breast cancer SAN DIEGO , May 20, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery
-
Company to host conference call and webcast today, May 12, at 5:00 p.m. EDT / 2:00 p.m. PDT SAN DIEGO , May 12, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological
-
Management to host conference call and webcast on May 12th at 5:00 pm EDT / 2:00 pm PDT SAN DIEGO , May 06, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways,
-
Abstracts originally accepted for presentation at the 2020 American Thoracic Society (ATS) International Conference Findings confirm that aTyr’s lead clinical candidate, ATYR1923, selectively binds to Neuropilin-2 (NRP2), a unique target expressed on key immune cells in inflammatory conditions SAN
-
SAN DIEGO , April 21, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that the U.S. Food and Drug Administration (FDA) has accepted its
-
Company to host conference call and webcast today at 5:00 p.m. EDT / 2:00 p.m. PDT SAN DIEGO , March 26, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today
-
Grant awarded by the Hong Kong Government's Innovation and Technology Commission under the Partnership Research Program Two-year project will initially focus on development of new bi-specific antibodies targeting NRP2 SAN DIEGO , March 24, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc.
-
Management to host conference call and webcast at 5:00 pm EST / 2:00 pm PST SAN DIEGO , March 19, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today